Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Jan 21, 2024 10:46am
60 Views
Post# 35837868

RE:RE:Macimorelin

RE:RE:Macimorelin
Alex1726 wrote:
Macimorelin could be a very valuable asset , maybe more than PGX. Make your own opinion and share it.

https://www.evaluate.com/vantage/articles/news/deals/flipping-win-strongbridge-biopharma


Based on PGX CoQ10 results published in Oct., 2023 I would say that PGX could easily attract a partner to fund the next commercial stage, so it definitely has more potential esp. given that PGX is a delivery system for bioactives with endless possibilities.

https://stockhouse.com/news/press-releases/2022/10/13/ceapro-inc-announces-positive-data-from-bioavailability-studies-evaluating-coq10

We just need a CEO who cares about shareholders who can make a commerical deal, and BTW, a PGX CoQ10 deal was a target for H2 2023. That was likely put on the backburner as priority was given to the self serving desire to have AEZS take over CZO's dirsuptive PGX tech so it could be used as a lifeline so AEZS could tout it to raise funds.
<< Previous
Bullboard Posts
Next >>